[1]金晓,连烨,王鹏,等.胶质母细胞瘤lncRNA-ROR的表达及其临床意义[J].中国临床神经外科杂志,2022,27(01):34-36.[doi:10.13798/j.issn.1009-153X.2021.01.012]
　JIN Xiao,LIAN Ye,WANG Peng,et al.Expression of lncRNA-ROR in glioblastoma tissues and its clinical meanings[J].,2022,27(01):34-36.[doi:10.13798/j.issn.1009-153X.2021.01.012]
点击复制

胶质母细胞瘤lncRNA-ROR的表达及其临床意义()
分享到：

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
27
期数:
2022年01期
页码:
34-36
栏目:
论著
出版日期:
2022-01-15

文章信息/Info

Title:
Expression of lncRNA-ROR in glioblastoma tissues and its clinical meanings
文章编号:
1009-153X（2022）01-0034-03
作者:
金晓;  连烨;  王鹏;  冯三江
473000 河南，南阳市第一人民医院神经外科（金晓、连烨、王鹏、冯三江）
Author(s):
JIN Xiao;  LIAN Ye;  WANG Peng;  FENG San-jiang.
Department of Neurosurgery, Nanyang First People's Hospital, Nanyang 473000, China
关键词:
胶质母细胞瘤; 长链非编码RNA重编程调节因子; lncRNA-ROR; 危险因素; 预后
Keywords:
Glioblastoma;  Long chain noncoding RNA reprogramming regulator;  Risk factors;  Prognosis
分类号:
R 739.41; Q 786
DOI:
10.13798/j.issn.1009-153X.2021.01.012
文献标志码:
A
摘要:
目的探讨长链非编码RNA重编程调节因子（lncRNA-ROR）在胶质母细胞瘤（GBM）中的表达情况及其与病人预后的关系。方法选取2015年6月~2019年6月手术切除的GBM组织145例，取同期颅脑损伤内减压术切除非肿瘤脑组织56例为对照，采用qRT-PCR法检测lncRNA-ROR的相对表达量，根据lncRNA-ROR平均表达水平分为高表达和低表达。术后随访24个月，记录无进展生存期和总生存期。结果GBM组织lncRNA-ROR表达水平明显低于对照组（P<0.05）。多因素Cox回归分析显示lncRNA-ROR低表达是GBM生存预后不良的独立危险因素（P<0.05）。生存曲线分析显示，lncRNA-ROR高表达组2年累积无进展生存率（40.12%）与2年累积总生存率（48.56%）明显高于低表达组（分别为16.25%、19.85%；P<0.05）。结论GBM组织lncRNA-ROR呈低表达，与病人不良生存预后密切相关。这提示检测lncRNA-ROR对GBM病人预后具有一定评估价值。
Abstract:
Objective To investigate the expression of long chain noncoding RNA reprogramming regulator (lncRNA-ROR) in glioblastoma (GBM) tissues and its clinical meanings. Methods The expression levels lncRNA-ROR were detected using qRT-PCR in GBM tissues obtained from 145 GBM patients who underwent microsurgery and in non-tumor cerebral tissues obtained from 56 patients with trauatic brain injury who underwent decompression from June 2015 to June 2019. GBM patients were divided into high-expression and low-expression groups according to the average expression level of lncRNA-ROR. The patients with GBM were followed up for 24 months, and the progression-free survival (PFS) and overall survival (OS) were recorded. Results The expression level of lncRNA-ROR in GBM tissues was significantly lower than that in the control group (P<0.05). Multivariate Cox regression analysis showed that low expression of lncRNA-ROR was an independent risk factor for poor survival prognosis of GBM patients (P<0.05). Survival curve analysis showed that the 2-year cumulative PFS rate (40.12%) and 2-year cumulative OS rate (48.56%) of the lncRNA-ROR high-expression group were significantly higher than those (16.25% and 19.85%, respectively) of the low expression group (P<0.05). Conclusions The expression of lncRNA-ROR is low in GBM tissues, which is closely related to the poor survival prognosis of GBM patients. This suggests that the detection of lncRNA-ROR has a certain value in the prognosis evaluation of GBM patients.

参考文献/References:

[1]Lee JK, Wang J, Sa JK, et al. Spatiotemporal genomic architecture informs precision oncology in glioblastoma[J]. Nat Genet, 2017, 49(4): 594-599.
[2]Paul Y, Thomas S, Patil V, et al. Genetic landscape of long noncoding RNA (lncRNAs) in glioblastoma: identification of complex lncRNA regulatory networks and clinically relevant lncRNAs in glioblastoma[J]. Oncotarget, 2018, 9(51): 29548-29564.
[3]黄立宁，冷开明，徐艺，等. 长链非编码RNA ROR在肿瘤中的表达和作用[J]. 现代医学，2017，45（12）：1865-1870.
[4]Polivka JJ, Polivka J, Holubec L, et al. Advances in experimental targeted therapy and immunotherapy for patients with glioblastoma multiforme[J]. Anticancer Res, 2017, 37(1): 21-33.
[5]任铭新，王可心，方一帆，等. 胶质母细胞瘤的分子生物学研究进展[J]. 肿瘤学杂志，2017，23（10）：863-867.
[6]Li MD, Long SG, Hu JQ, et al. Systematic identification of lncRNA-based prognostic biomarkers for glioblastoma[J].Aging, 2019, 11(21): 9405-9423.
[7]Li S, Yue XC, Sun CY, et al. Prognostic value of long noncoding RNA ROR in patients with cancer in China: a systematic review and meta-analysis[J]. Medicine, 2019, 98(21): e15758.
[8]李会俭，付军，赵敏，等. LincRNA-ROR在高级别浆液性卵巢癌中的表达及临床意义[J]. 中国临床研究，2019，32（4）：538-541.
[9]吴立春，谷仕艳，代黄梅，等. 长链非编码RNA-ROR在乳腺癌患者血清、癌组织中的表达变化及其临床意义[J].山东医药，2017，57（32）：78-80.
[10]Feng S, Yao J, Chen Y, et al. Expression and functional role of reprogramming-related long noncoding RNA (lincRNA-ROR) in glioma[J]. J Mol Neurosci, 2015, 56(3):623-630.
[11]黄书岚，刘宇航，王辉，等. 胶质母细胞瘤治疗现状和化疗药物研究进展[J]. 中国医药导报，2017，14（35）：29-32.
[12]郑宗泰，尹雷，王鹏，等. 胶质母细胞瘤切除术后128例预后因素分析[J]. 广东医学，2019，40（11）：1568-1572.
[13]Li Y, He ZC, Liu Q, et al. Large intergenic non-coding RNA-RoR inhibits aerobic glycolysis of glioblastoma cells via Akt pathway[J]. J Cancer, 2018, 9(5): 880-888.

相似文献/References:

[1]谢宝树　张　林　王　宇　贾　锋　殷玉华.复发性多发胶质母细胞瘤的预后分析[J].中国临床神经外科杂志,2016,(06):333.[doi:10.13798/j.issn.1009-153X.2016.06.005]
　XIE Bao-shu,ZHANG Lin,WANG Yu,et al.Analysis of prognoses in patients with recurrent multiple glioblastomas[J].,2016,(01):333.[doi:10.13798/j.issn.1009-153X.2016.06.005]
[2]宋贵东 综述　高之宪 审校.贝伐单抗治疗复发胶质母细胞瘤的研究进展[J].中国临床神经外科杂志,2015,(10):638.[doi:10.13798/j.issn.1009-153X.2015.10.022]
[3]李继强　杨吉安　邵灵敏　吴庭枫　刘宝辉　陈谦学.稳定低表达BAG3的胶质母细胞瘤U87细胞株的构建及鉴定[J].中国临床神经外科杂志,2015,(06):353.[doi:10.13798/j.issn.1009-153X.2015.06.011]
　LI Ji-qiang,YANG Ji-an,SHAO Ling-min,et al.Construction and identification of U87 glioblastoma cell strain with a stable low expression of BAG3[J].,2015,(01):353.[doi:10.13798/j.issn.1009-153X.2015.06.011]
[4]桂志勇　冯　军　黄俊红　白敬洋.靶向沉默c-fos基因表达对胶质瘤U87MG细胞增殖与侵袭的影响[J].中国临床神经外科杂志,2017,(12):834.[doi:10.13798/j.issn.1009-153X.2017.12.011]
　GUI Zhi-yong,FENG Jun,HUANG Jun-hong,et al.Effects of c-fos targeted silence on proliferation and invasiveness of human glioma cell U87[J].,2017,(01):834.[doi:10.13798/j.issn.1009-153X.2017.12.011]
[5]王娇燕　孟凡华　刘魏然　魏春晓　林丽萍.SWI在胶质母细胞瘤与单发脑转移瘤鉴别中的价值[J].中国临床神经外科杂志,2018,(01):13.[doi:10.13798/j.issn.1009-153X.2018.01.005]
　WANG Jiao-yan,MENG Fan-hua,LIU Wei-ran,et al.Value of susceptibility-weighted imaging in differentiative diagnosis of glioblastomas and solitary brain metastases[J].,2018,(01):13.[doi:10.13798/j.issn.1009-153X.2018.01.005]
[6]张治元　王汉东　樊友武　贾　玥　吴晋蓉.胶质肉瘤15例分析及文献复习[J].中国临床神经外科杂志,2018,(02):69.
　ZHANG Zhi-yuan,WANG Han-dong,FAN You-wu,et al.Diagnosis and treatment of gliosarcoma: a report of 15 cases and literature review[J].,2018,(01):69.
[7]郑锐哲　姜秀峰　陈二涛　孙兆良　冯东福.胶质母细胞瘤卒中术后继发硬膜下水瘤1例[J].中国临床神经外科杂志,2019,(02):128.[doi:10.13798/j.issn.1009-153X.2019.02.022]
[8]胡 玥,薛小燕,李子超,等.阿苯达唑抑制胶质瘤裸鼠模型肿瘤生长[J].中国临床神经外科杂志,2019,(06):348.[doi:10.13798/j.issn.1009-153X.2019.06.010]
　HU Yue,XUE Xiao-yan,LI Zi-chao,et al.Albendazole inhibits tumor growth in nude mice model of glioma[J].,2019,(01):348.[doi:10.13798/j.issn.1009-153X.2019.06.010]
[9]殷安安　陆　南　贺亚龙　章　翔　刘玉河.TRIM38基因非CpG岛DNA甲基化与胶质母细胞瘤临床预后的关系[J].中国临床神经外科杂志,2020,(02):76.[doi:10.13798/j.issn.1009-153X.2020.02.005]
　YIN An-an,LU Nan,HE Ya-long,et al.Impacts of TRIM38 non-CpG island DNA methylation alterations on clinical prognosis in patients with glioblastomas[J].,2020,(01):76.[doi:10.13798/j.issn.1009-153X.2020.02.005]
[10]吴　蛟　易　勇　赵卓琳　周良学　周世军.贝伐珠单抗联合化疗治疗胶质母细胞瘤的meta分析[J].中国临床神经外科杂志,2020,(02):82.[doi:10.13798/j.issn.1009-153X.2020.02.007]
　WU Jiao,YI Yong,ZHAO Zhuo-lin,et al.Efficacy and safety of bevacizumab combined with chemotherapy for glioblastoma: a meta-analysis[J].,2020,(01):82.[doi:10.13798/j.issn.1009-153X.2020.02.007]

更新日期/Last Update: 2022-01-18